Indication
Recurrent Uterine Corpus Carcinosarcoma
1 clinical trial
3 products
Clinical trial
Phase I Trial of Intravenous Administration of Vesicular Stomatitis Virus Genetically Engineered to Express Thyroidal Sodium Iodide Symporter (NIS) and Human Interferon Beta (hIFNb), in Patients With Metastatic or Recurrent Endometrial CancerStatus: Active (not recruiting), Estimated PCD: 2024-06-01
Product
Recombinant Vesicular Stomatitis Virus-expressing Human Interferon Beta and Sodium-Iodide SymporterProduct
Ruxolitinib